Sagespring Wealth Partners LLC Makes New $299,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Sagespring Wealth Partners LLC has made a new investment of approximately $299,000 in Alnylam Pharmaceuticals, acquiring 916 shares during the 2nd quarter.
• Alnylam Pharmaceuticals reported an earnings per share (EPS) of $0.32 for the last quarter, exceeding analysts' expectations, and had revenue of $773.69 million, reflecting a 17.3% increase year-over-year.
• A number of institutional investors have increased their holdings in Alnylam Pharmaceuticals, with institutional ownership currently at 92.97%.

Sagespring Wealth Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 916 shares of the biopharmaceutical company's stock, valued at approximately $299,000.

A number of other institutional investors have also recently made changes to their positions in ALNY. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. GAMMA Investing LLC increased its holdings in shares of Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after acquiring an additional 77 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Alnylam Pharmaceuticals by 14.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 14,404 shares of the biopharmaceutical company's stock valued at $3,889,000 after purchasing an additional 1,838 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Alnylam Pharmaceuticals by 97.9% in the 1st quarter. QRG Capital Management Inc. now owns 1,949 shares of the biopharmaceutical company's stock worth $526,000 after purchasing an additional 964 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Alnylam Pharmaceuticals by 33.9% in the 1st quarter. Blue Trust Inc. now owns 1,158 shares of the biopharmaceutical company's stock worth $313,000 after purchasing an additional 293 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $481.67 on Friday. The business's 50-day moving average is $455.90 and its two-hundred day moving average is $352.20. The company has a market capitalization of $63.14 billion, a P/E ratio of -195.01 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $492.62. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an "overweight" rating for the company in a research note on Monday, October 13th. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Finally, Barclays increased their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $463.08.

Insider Activity

In other news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company's stock, valued at $362,390. The trade was a 95.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.